Do analysts rate SLXN or BOLT?

Bolt Biotherapeutics has a consensus price target of $14.50, suggesting a potential upside of 272.75%. Given Bolt Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Silexion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bolt Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts recommend SLXN or AQB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SLXN or AQB more profitable?

AquaBounty Technologies' return on equity of -147.07% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silexion Therapeutics N/A -563.11% -201.73% AquaBounty Technologies N/A -147.07% -28.73%

Do analysts recommend SLXN or PMCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, SLXN or PMCB?

Nuvilex is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silexion Therapeutics N/A N/A -$11.91M -$42.47 N/A Nuvilex N/A N/A -$19.42M -$3.00 N/A

Is SLXN or PMCB more profitable?

Nuvilex's return on equity of 0.25% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silexion Therapeutics N/A -563.11% -201.73% Nuvilex N/A 0.25% 0.18%

Do analysts rate SLXN or LABT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, SLXN or LABT?

Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silexion Therapeutics N/A N/A -$11.91M -$42.47 N/A Lakewood-Amedex Biotherapeutics N/A N/A -$3.85M -$4.75 N/A

Is SLXN or LABT more profitable?

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silexion Therapeutics N/A -563.11% -201.73% Lakewood-Amedex Biotherapeutics N/A N/A N/A

Do analysts recommend SLXN or XTLB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SLXN or XTLB more profitable?

XTL Biopharmaceuticals' return on equity of 0.00% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silexion Therapeutics N/A -563.11% -201.73% XTL Biopharmaceuticals N/A N/A N/A

Silexion Therapeutics (SLXN) Competitors

$0.35 +0.00 (+0.11%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$0.37 +0.02 (+5.52%)

As of 05:02 AM Eastern

Compare

SLXN vs. BOLT, AQB, PMCB, LABT, and XTLB

Should you buy Silexion Therapeutics stock or one of its competitors? Silexion Therapeutics's main competitors and comparable companies include Bolt Biotherapeutics (BOLT), AquaBounty Technologies (AQB), Nuvilex (PMCB), Lakewood-Amedex Biotherapeutics (LABT), and XTL Biopharmaceuticals (XTLB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Silexion Therapeutics compare to Bolt Biotherapeutics?

Silexion Therapeutics (NASDAQ:SLXN) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

Silexion Therapeutics has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Bolt Biotherapeutics' return on equity of -126.23% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-563.11%	-201.73%
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%

Silexion Therapeutics has higher earnings, but lower revenue than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$42.47	N/A
Bolt Biotherapeutics	$4.70M	1.59	-$33.38M	-$16.44	N/A

11.0% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 0.8% of Silexion Therapeutics shares are held by company insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Silexion Therapeutics has a beta of -0.36, indicating that its stock price is 136% less volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Bolt Biotherapeutics has a consensus price target of $14.50, suggesting a potential upside of 272.75%. Given Bolt Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Silexion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Silexion Therapeutics' average media sentiment score of 0.00 equaled Bolt Biotherapeutics'average media sentiment score.

Company	Overall Sentiment
Silexion Therapeutics	Neutral
Bolt Biotherapeutics	Neutral

Summary

Bolt Biotherapeutics beats Silexion Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Silexion Therapeutics compare to AquaBounty Technologies?

Silexion Therapeutics (NASDAQ:SLXN) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

AquaBounty Technologies' return on equity of -147.07% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-563.11%	-201.73%
AquaBounty Technologies	N/A	-147.07%	-28.73%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.0% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are owned by institutional investors. 0.8% of Silexion Therapeutics shares are owned by company insiders. Comparatively, 1.0% of AquaBounty Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Silexion Therapeutics has a beta of -0.36, meaning that its stock price is 136% less volatile than the broader market. Comparatively, AquaBounty Technologies has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

Silexion Therapeutics has higher earnings, but lower revenue than AquaBounty Technologies. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$42.47	N/A
AquaBounty Technologies	$2.47M	2.46	-$18.49M	-$0.82	N/A

In the previous week, Silexion Therapeutics' average media sentiment score of 0.00 equaled AquaBounty Technologies'average media sentiment score.

Company	Overall Sentiment
Silexion Therapeutics	Neutral
AquaBounty Technologies	Neutral

Summary

AquaBounty Technologies beats Silexion Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Silexion Therapeutics compare to Nuvilex?

Silexion Therapeutics (NASDAQ:SLXN) and Nuvilex (NASDAQ:PMCB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

11.0% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of Nuvilex shares are owned by institutional investors. 0.8% of Silexion Therapeutics shares are owned by insiders. Comparatively, 11.0% of Nuvilex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Nuvilex is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$42.47	N/A
Nuvilex	N/A	N/A	-$19.42M	-$3.00	N/A

In the previous week, Silexion Therapeutics' average media sentiment score of 0.00 equaled Nuvilex'saverage media sentiment score.

Company	Overall Sentiment
Silexion Therapeutics	Neutral
Nuvilex	Neutral

Silexion Therapeutics has a beta of -0.36, meaning that its stock price is 136% less volatile than the broader market. Comparatively, Nuvilex has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuvilex's return on equity of 0.25% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-563.11%	-201.73%
Nuvilex	N/A	0.25%	0.18%

Summary

Nuvilex beats Silexion Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Silexion Therapeutics compare to Lakewood-Amedex Biotherapeutics?

Silexion Therapeutics (NASDAQ:SLXN) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

In the previous week, Lakewood-Amedex Biotherapeutics had 5 more articles in the media than Silexion Therapeutics. MarketBeat recorded 5 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Silexion Therapeutics. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.98 beat Silexion Therapeutics' score of 0.00 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Silexion Therapeutics	Neutral
Lakewood-Amedex Biotherapeutics	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$42.47	N/A
Lakewood-Amedex Biotherapeutics	N/A	N/A	-$3.85M	-$4.75	N/A

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-563.11%	-201.73%
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A

11.0% of Silexion Therapeutics shares are held by institutional investors. 0.8% of Silexion Therapeutics shares are held by company insiders. Comparatively, 5.4% of Lakewood-Amedex Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Lakewood-Amedex Biotherapeutics beats Silexion Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Silexion Therapeutics compare to XTL Biopharmaceuticals?

Silexion Therapeutics (NASDAQ:SLXN) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

In the previous week, Silexion Therapeutics' average media sentiment score of 0.00 equaled XTL Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Silexion Therapeutics	Neutral
XTL Biopharmaceuticals	Neutral

Silexion Therapeutics has a beta of -0.36, suggesting that its share price is 136% less volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

XTL Biopharmaceuticals' return on equity of 0.00% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-563.11%	-201.73%
XTL Biopharmaceuticals	N/A	N/A	N/A

XTL Biopharmaceuticals has higher revenue and earnings than Silexion Therapeutics. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$42.47	N/A
XTL Biopharmaceuticals	$450K	12.22	-$6.97M	-$0.64	N/A

11.0% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 0.8% of Silexion Therapeutics shares are owned by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

XTL Biopharmaceuticals beats Silexion Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Silexion Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLXN vs. The Competition

Export

Metric	Silexion Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.95M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.01	12.66	273.29	25.25
Price / Sales	N/A	1,342.79	623.67	97.64
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	35.16	16.39	12.92	6.14
Net Income	-$11.91M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-3.09%	0.36%	0.60%	-0.27%
1 Month Performance	-81.49%	8.53%	5.72%	0.68%
1 Year Performance	-99.50%	52.66%	25.33%	14.84%

Silexion Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLXN Silexion Therapeutics	0.4342 of 5 stars	$0.35 +0.1%	N/A	-99.5%	$1.95M	N/A	N/A	N/A	Gap Up
BOLT Bolt Biotherapeutics	2.477 of 5 stars	$3.83 -0.5%	$14.50 +278.6%	-19.7%	$7.38M	$4.70M	N/A	90	Positive News
AQB AquaBounty Technologies	0.1497 of 5 stars	$1.28 -4.1%	N/A	+0.9%	$6.57M	$2.47M	N/A	100
PMCB Nuvilex	0.8453 of 5 stars	$0.54 +0.6%	N/A	-48.8%	$5.83M	N/A	N/A	4	Positive News Analyst Downgrade
LABT Lakewood-Amedex Biotherapeutics	0.9036 of 5 stars	$2.45 +7.0%	N/A	N/A	$5.81M	N/A	N/A	5	News Coverage Positive News Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLXN) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silexion Therapeutics (SLXN) Competitors

SLXN vs. BOLT, AQB, PMCB, LABT, and XTLB

How does Silexion Therapeutics compare to Bolt Biotherapeutics?

Summary

How does Silexion Therapeutics compare to AquaBounty Technologies?

Summary

How does Silexion Therapeutics compare to Nuvilex?

Summary

How does Silexion Therapeutics compare to Lakewood-Amedex Biotherapeutics?

Summary

How does Silexion Therapeutics compare to XTL Biopharmaceuticals?

Summary

Media Sentiment Over Time

SLXN vs. The Competition

Silexion Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silexion Therapeutics (SLXN) Competitors

SLXN vs. BOLT, AQB, PMCB, LABT, and XTLB

How does Silexion Therapeutics compare to Bolt Biotherapeutics?

Is SLXN or BOLT more profitable?

Which has stronger earnings & valuation, SLXN or BOLT?

Do insiders and institutionals have more ownership in SLXN or BOLT?

Which has more volatility and risk, SLXN or BOLT?

Do analysts rate SLXN or BOLT?

Does the media refer more to SLXN or BOLT?

Summary

How does Silexion Therapeutics compare to AquaBounty Technologies?

Is SLXN or AQB more profitable?

Do analysts recommend SLXN or AQB?

Do institutionals and insiders believe in SLXN or AQB?

Which has more risk and volatility, SLXN or AQB?

Which has stronger earnings and valuation, SLXN or AQB?

Does the media favor SLXN or AQB?

Summary

How does Silexion Therapeutics compare to Nuvilex?

Do institutionals & insiders believe in SLXN or PMCB?

Which has better valuation and earnings, SLXN or PMCB?

Does the media favor SLXN or PMCB?

Which has more volatility and risk, SLXN or PMCB?

Do analysts recommend SLXN or PMCB?

Is SLXN or PMCB more profitable?

Summary

How does Silexion Therapeutics compare to Lakewood-Amedex Biotherapeutics?

Does the media prefer SLXN or LABT?

Do analysts rate SLXN or LABT?

Which has higher earnings and valuation, SLXN or LABT?

Is SLXN or LABT more profitable?

Do institutionals and insiders believe in SLXN or LABT?

Summary

How does Silexion Therapeutics compare to XTL Biopharmaceuticals?

Does the media favor SLXN or XTLB?

Which has more volatility and risk, SLXN or XTLB?

Do analysts recommend SLXN or XTLB?

Is SLXN or XTLB more profitable?

Which has higher valuation and earnings, SLXN or XTLB?

Do institutionals & insiders have more ownership in SLXN or XTLB?

Summary

Media Sentiment Over Time

SLXN vs. The Competition

Silexion Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools